Business Context and Reporting Period
This Form 8-K is a current report filed by GlycoMimetics, Inc. (not Crescent Biopharma, Inc., as indicated in the metadata) on February 19, 2021. The report discloses material corporate governance changes regarding the departure of a senior officer and the subsequent appointment of a successor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
- Resignation: Helen Thackray, M.D., FAAP, resigned as Senior Vice President, Clinical Development, and Chief Medical Officer effective March 19, 2021, to pursue other business opportunities.
- Appointment: Eric J. Feldman, M.D., was promoted from Vice President, Clinical Development, to Senior Vice President and Chief Medical Officer.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or specific risk factors beyond the operational impact of the leadership transition. The company issued a press release on February 23, 2021, detailing these changes, which is included as Exhibit 99.1 but is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the exact effective date of Dr. Thackray's departure (March 19, 2021).
- Confirm Dr. Feldman's new title and responsibilities as Chief Medical Officer.
- Review the press release (Exhibit 99.1) for any additional context on the transition plan not included in the 8-K text.
- Note the discrepancy between the metadata company name (Crescent Biopharma) and the actual registrant (GlycoMimetics).